Epiminder builds U.S. trial momentum as cash reserves underpin epilepsy device rollout

Epiminder Ltd. ( (AU:EPI) ) has shared an announcement.

Epiminder reported accelerating momentum in its DETECT reimbursement study, with 18 leading U.S. medical centres now contracted and patient enrolment rising to 15, keeping the company on track to reach 25 participants by the end of May and 210 patients by mid-2027. Management said strong interest from top institutions such as Stanford and the University of North Carolina underpins confidence in the clinical and commercial potential of the Minder device and supports its planned full market rollout in early 2028.

The company also confirmed that development of its next-generation G1 device remains on schedule for completion by mid-2027 and subsequent U.S. regulatory submission later that year. Epiminder ended the March quarter with $83.8 million in cash and no debt, expects lower-than-previously-indicated cash burn of about $17 million in the second half of FY26, and says its balance sheet should fund commercialisation plans and ongoing trials well into 2028 despite timing impacts from slower U.S. site invoicing.

The most recent analyst rating on (AU:EPI) stock is a Buy with a A$2.33 price target. To see the full list of analyst forecasts on Epiminder Ltd. stock, see the AU:EPI Stock Forecast page.

More about Epiminder Ltd.

Epiminder Limited is an ASX-listed medical device company developing Minder, an FDA-authorised implantable continuous EEG monitoring system for people with epilepsy. The company focuses on long-term brain monitoring to support diagnosis, management and reimbursement pathways in major U.S. epilepsy centres, targeting full commercial rollout of its technology in the coming years.

Average Trading Volume: 77,868

Technical Sentiment Signal: Strong Sell

For a thorough assessment of EPI stock, go to TipRanks’ Stock Analysis page.